Compare Neurocrine Biosciences Inc (NBIX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Western Alliance Bancorporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WAL | |
|---|---|---|
Market Cap | $17.40B | $8.84B |
Sector | Health | Financials |
52-Week High | $180.55 | $96.08 |
52-Week Low | $123.10 | $66.70 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 2.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
